Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot, Israel.
Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel.
Oncogene. 2017 Jun 29;36(26):3686-3694. doi: 10.1038/onc.2016.523. Epub 2017 Feb 6.
The tyrosine phosphatase PTPROt is a suggested tumor suppressor (TS) in B-cell chronic lymphocytic leukemia (CLL), and its expression is reduced in this disease. In order to examine how reduced PTPROt expression affects CLL in vivo we induced CLL in PTPROt-targeted mice. Unexpectedly, loss of both Ptprot alleles delayed disease detection and progression and lengthened survival relative to mice carrying two intact alleles, indicating that PTPROt fulfills a novel tumor-promoting role in CLL. Tumor cells from mice lacking PTPROt exhibited reduced B-cell receptor (BCR)-induced signaling, as well as increased apoptosis and autophagy. Inhibition of BCR/Src signaling in CLL cells induced their apoptosis, indicating that these findings are linked causally. These results suggest a cell-autonomous mechanism for the weakened CLL phenotype of PTPROt-deficient mice and uncover non-redundant roles for PTPROt in support of BCR signaling and survival of CLL cells. In contrast, loss of only one Ptprot allele induced earlier detection and progression of CLL and reduced survival, consistent with a tumor-suppressing role for PTPROt. Tumor cells from mice lacking one or both Ptprot allele exhibited increased interleukin-10 (IL-10) expression and signaling, factors known to support CLL; cells lacking one Ptprot alleles exhibited normal BCR signaling and cell death rates. We conclude that loss of one Ptprot allele promotes CLL, most likely by activating IL-10 signaling. Loss of both Ptprot alleles also reduces BCR signaling and increases cell death rates, offsetting the IL-10 effects and reducing the severity of the disease. PTPROt thus functions as an obligate haploinsufficient TS in CLL, where its expression levels determine its role as a promoter or inhibitor of the tumorigenic process in mice. Partial loss of PTPROt generates the strongest disease phenotype, suggesting that its intermediate expression levels in CLL are selected for.
酪氨酸磷酸酶 PTPROt 是 B 细胞慢性淋巴细胞白血病 (CLL) 中的一种肿瘤抑制因子(TS),其在该疾病中的表达减少。为了研究 PTPROt 表达减少如何在体内影响 CLL,我们在 PTPROt 靶向小鼠中诱导 CLL。出乎意料的是,与携带两个完整等位基因的小鼠相比,两个 Ptprot 等位基因的缺失延迟了疾病的检测和进展,并延长了生存时间,表明 PTPROt 在 CLL 中发挥了新的促肿瘤作用。缺乏 PTPROt 的肿瘤细胞表现出 B 细胞受体(BCR)诱导的信号转导减少,以及凋亡和自噬增加。在 CLL 细胞中抑制 BCR/Src 信号转导诱导其凋亡,表明这些发现存在因果关系。这些结果表明 PTPROt 缺失小鼠的 CLL 表型减弱是一种细胞自主机制,并揭示了 PTPROt 在支持 BCR 信号转导和 CLL 细胞存活方面的非冗余作用。相比之下,仅缺失一个 Ptprot 等位基因会导致 CLL 更早的检测和进展,并降低生存时间,这与 PTPROt 的肿瘤抑制作用一致。缺失一个或两个 Ptprot 等位基因的肿瘤细胞表现出白细胞介素-10(IL-10)表达和信号增加,这些因子已知支持 CLL;缺失一个 Ptprot 等位基因的细胞表现出正常的 BCR 信号转导和细胞死亡率。我们得出结论,缺失一个 Ptprot 等位基因促进 CLL,最有可能通过激活 IL-10 信号转导。两个 Ptprot 等位基因的缺失也会降低 BCR 信号转导并增加细胞死亡率,从而抵消 IL-10 的作用并降低疾病的严重程度。因此,PTPROt 在 CLL 中作为必需的杂合不足 TS 发挥作用,其表达水平决定了其在小鼠中作为肿瘤发生过程的促进剂或抑制剂的作用。PTPROt 的部分缺失产生最强的疾病表型,这表明其在 CLL 中的中间表达水平是被选择的。